What is IGF-1 LR3?
Compound Spotlight
IGF-1 LR3 is one of the few compounds in this catalog with a genuine, uncontroversial, mainstream research application: it is a standard reagent in mammalian cell culture, used in laboratories and biomanufacturing worldwide. Understanding why it exists in that context explains both what it does and why its design is what it is.
Quick summary
- An 83-amino-acid analog of human IGF-1: the native 70-residue protein plus a 13-residue N-terminal extension, with arginine substituted for glutamate at position 3.
- Both modifications sharply reduce binding to IGF-binding proteins (IGFBPs), which normally sequester over 95% of circulating IGF-1.
- Escaping IGFBP control extends its functional activity dramatically compared to native IGF-1.
- Its established use is as a cell culture supplement, where it outperforms native IGF-1 because culture media contain IGFBPs that would otherwise neutralize it.
- Signals through the IGF-1 receptor, activating PI3K/Akt and MAPK pathways — growth, proliferation, and anti-apoptotic signaling.
- Genuine concerns: cross-reactivity with the insulin receptor at high concentrations, and the well-documented association between IGF-1 signaling and cancer biology.
The IGFBP problem it was built to solve
Native IGF-1 does not circulate freely. More than 95% of it is bound to a family of six IGF-binding proteins, principally IGFBP-3, which act as both reservoir and brake: they extend the hormone’s circulating lifespan while preventing it from engaging receptors until released. Free IGF-1 has a half-life measured in minutes.
For a researcher trying to study IGF-1 receptor signaling, this is an obstacle. Add native IGF-1 to a culture system containing IGFBPs and most of it is captured before it reaches a receptor, making dose-response relationships unreliable and effects inconsistent.
What the modifications do
LR3 carries two changes. The “R3” refers to the substitution of arginine for glutamate at position three, which disrupts a contact point used in IGFBP binding. The “Long” refers to a 13-amino-acid extension added at the N-terminus, which further reduces IGFBP affinity.
Together these reduce IGFBP binding by roughly two to three orders of magnitude while preserving affinity for the IGF-1 receptor itself. The result is a molecule that behaves as though the binding-protein system were not there — which is precisely the intent. Reported functional potency in culture is substantially greater than native IGF-1, not because it engages the receptor more strongly, but because far more of it survives to do so.
Downstream signaling
The IGF-1 receptor is a receptor tyrosine kinase structurally similar to the insulin receptor. Activation triggers two principal cascades. The PI3K/Akt pathway drives protein synthesis, glucose uptake, and suppression of apoptosis — it is a major survival signal, and connects to mTOR. The MAPK/ERK pathway drives proliferation and differentiation.
The structural similarity between the IGF-1 and insulin receptors has a practical consequence: at sufficiently high concentrations, IGF-1 analogs cross-react with the insulin receptor and can produce insulin-like effects on blood glucose. This is a recognized property of the molecule, not a fringe concern, and it is one reason concentration control matters in any system where it is used.
Its actual research role
LR3 IGF-1 is widely used as a serum-free media supplement in mammalian cell culture, including industrial bioprocessing with CHO cells for recombinant protein production. In that setting its advantage is straightforward and well documented: it supports cell growth and viability at lower concentrations than native IGF-1 because it resists the IGFBPs present in the system.
In laboratory research it serves as a tool for studying sustained IGF-1 receptor activation over defined experimental windows — muscle cell differentiation, neuronal survival, general growth-signaling work. Its value is methodological: it makes IGF-1 receptor pharmacology tractable.
The cancer-signaling question
Any honest treatment of IGF-1 has to address this. IGF-1 signaling is one of the more thoroughly documented growth-promoting and anti-apoptotic pathways in cell biology, and elevated IGF-1 has been associated in epidemiological work with increased risk for several cancers. The same PI3K/Akt survival signaling that makes it useful for keeping cells alive in culture is a pathway frequently dysregulated in malignancy.
This does not make the molecule inherently dangerous in a culture dish, and IGF-1 is a normal, essential human hormone. But an analog engineered specifically to escape the body’s regulatory brake on that pathway is a meaningfully different proposition from the native hormone operating under normal control, and the absence of long-term data on unregulated IGF-1 receptor activation is a real gap rather than a technicality.
Frequently asked questions
What exactly do “Long” and “R3” refer to?
“Long” is the 13-amino-acid N-terminal extension; “R3” is the arginine-for-glutamate substitution at position 3. Both reduce IGF-binding-protein affinity.
Is LR3 more potent at the receptor than native IGF-1?
Not meaningfully. Its receptor affinity is comparable. The apparent potency difference comes from escaping IGFBP sequestration, so more of the molecule remains available to bind.
Why do cell culture media need it rather than native IGF-1?
Media and serum components include IGFBPs that bind and neutralize native IGF-1, making its effective concentration unpredictable. LR3 largely bypasses that, giving more consistent and reproducible results.
How do I know what is actually in the vial?
Every lot we sell has a published Certificate of Analysis from an independent, third-party lab confirming identity and purity. Lot numbers on the vial should match the COA you are referencing.
References
- Francis GL, et al. Insulin-like growth factor (IGF)-II binding to IGF-binding proteins and IGF receptors is modified by deletion of the N-terminal tripeptide. Biochem J. 1992.
- Tomas FM, et al. Anabolic effects of insulin-like growth factor-I (IGF-I) and an IGF-I variant in normal female rats. J Endocrinol. 1993.
- Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002;23(6):824–854.
- Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8(12):915–928.
View the IGF-1 LR3 product listing →
Read our growth hormone secretagogue guide →
Look up your lot Certificate of Analysis →
For laboratory and research use only. Not for human consumption. This article summarizes published research for informational purposes and is not medical advice, nor a recommendation or protocol for use.
Related research compounds
Arc Peptides supplies these compounds, each third-party tested for purity and identity with a lot-specific Certificate of Analysis:
For laboratory research use only. Not for human consumption.
